H. Ross

发表

Apoptosis of non-small-cell lung cancer cell lines after paclitaxel treatment involves the BH3-only proapoptotic protein Bim

R. Li, T. Moudgil, Hong-Ming Hu, 2005, Cell Death and Differentiation.

A phase II study of the safety and efficacy of the multidrug resistance inhibitor VX‐710 combined with doxorubicin and vincristine in patients with recurrent small cell lung cancer

Bruce E. Johnson, T. Lynch, C. Langer, 2007, Cancer.

Selective dose escalation of chemoradiotherapy for locally advanced esophageal cancer.

J. Smith, S. Seung, H. Ross, 2008, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

Selective dose escalation of chemoradiotherapy for esophageal cancer: role of treatment intensification.

J. Regan, J. W. Smith, John W. Smith, 2004, Seminars in oncology.

Gastroesophageal reflux disease and paraneoplastic neurological syndrome associated with long‐term survival in limited stage small‐cell lung cancer

J. Yi, K. Swanson, J. Wampfler, 2022, Thoracic cancer.

Randomized Phase II Trial of Cisplatin, Etoposide, and Radiation Followed by Gemcitabine Alone or by Combined Gemcitabine and Docetaxel in Stage III A/B Unresectable Non-small Cell Lung Cancer

C. Obasaju, S. Feigenberg, B. Movsas, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Survival of Patients Treated with High-dose Radiotherapy and Concurrent Chemotherapy for Unresectable Non-small-cell Lung Cancer

S. Schild, H. Ross, 2010 .

Phase II trial of combined modality therapy with concurrent topotecan plus radiotherapy followed by consolidation chemotherapy for unresectable stage III and selected stage IV non-small-lung cancer.

S. Seung, H. Ross, 2009, International journal of radiation oncology, biology, physics.

Clinical Characteristics of Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia

H. Kosiorek, T. Halfdanarson, D. Jaroszewski, 2020 .

Stereotactic body radiotherapy for early-stage non-small cell lung cancer has low post-treatment mortality.

T. Sio, S. Schild, D. Jaroszewski, 2018, Journal of thoracic disease.

Localized gastric or gastroesophageal cancer - chemoradiation is a pertinent component of adjuvant treatment for patients at high risk of relapse.

M. Borad, B. Pockaj, K. Harold, 2009, Gastrointestinal cancer research : GCR.

Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naïve patients with malignant pleural mesothelioma: outcomes of an expanded access program.

C. Obasaju, P. Jänne, A. Wozniak, 2007, Lung cancer.

Pemetrexed Alone or in Combination with Cisplatin in Previously Treated Malignant Pleural Mesothelioma: Outcomes from a Phase IIIB Expanded Access Program

C. Obasaju, P. Jänne, A. Wozniak, 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program.

C. Obasaju, P. Jänne, D. Mintzer, 2005, Clinical lung cancer.

An early experience using the technique of transoral OrVil EEA stapler for minimally invasive transthoracic esophagectomy.

D. Fleischer, K. Harold, Y. Romero, 2011, The Annals of thoracic surgery.

Phase III Trial Comparing Paclitaxel Poliglumex (CT-2103, PPX) in Combination with Carboplatin Versus Standard Paclitaxel and Carboplatin in the Treatment of PS 2 Patients with Chemotherapy-Naïve Advanced Non-small Cell Lung Cancer

M. Socinski, K. O'Byrne, T. Ciuleanu, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Clinical Characteristics of DIPNECH: A Retrospective Analysis.

H. Kosiorek, T. Halfdanarson, D. Jaroszewski, 2020, Chest.

Multimodality therapy improves survival in elderly patients with locally advanced non-small cell lung cancer—A retrospective analysis

A. Dueck, S. Schild, S. Vora, 2012 .

Efficacy of GM-CSF-producing Tumor Vaccine after Docetaxel Chemotherapy in Mice Bearing Established Lewis Lung Carcinoma

W. Urba, S. Xiong, K. Jooss, 2006, Journal of immunotherapy.

First Report of Dramatic Tumor Responses with Ramucirumab and Paclitaxel After Progression on Pembrolizumab in Two Cases of Metastatic Gastroesophageal Adenocarcinoma.

Haidong Dong, H. Yoon, H. Ross, 2018, The oncologist.

Early Outcomes of Patients With Locally Advanced Non-small Cell Lung Cancer Treated With Intensity-Modulated Proton Therapy Versus Intensity-Modulated Radiation Therapy: The Mayo Clinic Experience

T. Sio, J. Ashman, S. Schild, 2019, Advances in radiation oncology.

Serum-free estradiol (E2) levels are prognostic in men with chemotherapy-naive advanced non-small cell lung cancer (NSCLC) and performance status (PS) 2

J. Singer, P. Bonomi, F. Oldham, 2007 .

A phase II multicenter trial comparing two schedules of lapatinib (LAP) as first or second line monotherapy in subjects with advanced or metastatic non-small cell lung cancer (NSCLC) with either bronchioloalveolar carcinoma (BAC) or no smoking history

M. Berger, J. Rigas, F. Shepherd, 2007 .

O-101 XYOTAX™/carboplatin vs paclitaxel/carboplatin for the treatmentof PS2 patients with chemotherapy-naïve advanced non-small cell lung cancer (NSCLC): The stellar 3 phase III study

M. Socinski, K. O'Byrne, A. Szczesna, 2005 .

Biphasic Pulmonary Blastoma with Germ Cell Differentiation in a 36-Year-Old Man

M. Beasley, Patrick Archie, H. Ross, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Randomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer.

F. Shepherd, P. Ellis, D. Ellison, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Neuroendocrine-like differentiation of non-small cell lung carcinoma cells: regulation by cAMP and the interaction of mac25/IGFBP-rP1 and 25.1

R. Antoniono, Y. Oh, H. Ross, 2006, Oncogene.

Randomized phase II study of SGN-15 (CBR96-doxorubicin immunoconjugate) with docetaxel in patients with advanced or metastatic non-small cell lung cancer (NSCLC).

C. Rudin, R. Figlin, L. Hart, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Expanding the Spectrum of Radiation Necrosis After Stereotactic Radiosurgery (SRS) for Intracranial Metastases From Lung Cancer

M. Mrugala, R. Zimmerman, T. Sio, 2019, American journal of clinical oncology.

Effect of gender on outcome in two randomized phase III trials of paclitaxel poliglumex (PPX) in chemonaïve pts with advanced NSCLC and poor performance status (PS2).

M. Socinski, K. O'Byrne, L. Paz-Ares, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma.

A. Wozniak, L. Krug, J. Bauman, 2014, Lung cancer.

Safety and Clinical Activity of MEDI1873, a Novel GITR Agonist, in Advanced Solid Tumors

N. Rizvi, J. Infante, A. Naing, 2020, Clinical Cancer Research.

Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX® vaccine in advanced-stage non-small-cell lung cancer

B. Fox, J. Nemunaitis, D. Jablons, 2006, Cancer Gene Therapy.

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Young Hak Kim, N. Reinmuth, A. Chiang, 2019, The Lancet.

TG4010 immunotherapy combined with first-line therapy in advanced non-small cell lung cancer (NSCLC): phase IIb results of the TIME study

L. Sequist, J. Nemunaitis, E. Juhász, 2014, Journal of Immunotherapy for Cancer.

Outcomes on anti‐VEGFR‐2/paclitaxel treatment after progression on immune checkpoint inhibition in patients with metastatic gastroesophageal adenocarcinoma

Tsung-Teh Wu, N. Foster, H. Pitot, 2021, International journal of cancer.

Preliminary safety results of a phase II trial comparing two schedules of lapatinib (GW572016) as first line therapy for advanced or metastatic non-small cell lung cancer

J. Rigas, A. Dowlati, L. Leopold, 2005 .

Randomized, open-label, phase III study of pemetrexed plus carboplatin (PemC) followed by maintenance pemetrexed versus paclitaxel/carboplatin/bevacizumab (PCB) followed by maintenance bevacizumab in patients with advanced nonsquamous (NS) non-small cell lung cancer (NSCLC).

C. Obasaju, R. Govindan, D. Spigel, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I/II trial of low dose cyclosporin A with EP for advanced non-small cell lung cancer1

K. Osann, Siu-Fun Wong, L. Slater, 1997 .

M. Socinski, K. O'Byrne, T. Ciuleanu, 2008 .

Bullous pyoderma gangrenosum after granulocyte colony‐stimulating factor treatment

R. Figlin, R. Kaplan, H. Ross, 1991, Cancer.

A randomized, controlled study of an online intervention to promote job satisfaction and well-being among physicians

L. Dyrbye, T. Shanafelt, C. West, 2016 .

Randomized Phase II Multicenter Trial of Two Schedules of Lapatinib as First- or Second-Line Monotherapy in Patients with Advanced or Metastatic Non–Small Cell Lung Cancer

J. Rigas, F. Shepherd, M. Smylie, 2010, Clinical Cancer Research.

A phase I trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancer

R. Salgia, J. Stephenson, A. Chiappori, 2012, British Journal of Cancer.

A pilot study of an autologous tumor-derived autophagosome vaccine with docetaxel in patients with stage IV non-small cell lung cancer

B. Fox, W. Urba, E. Walker, 2017, Journal of Immunotherapy for Cancer.

Past approaches and future directions for targeting tumor hypoxia in squamous cell carcinomas of the head and neck.

W. Wong, H. Ross, K. Curtis, 2016, Critical reviews in oncology/hematology.

High and low dose rate irradiation have opposing effects on cytokine gene expression in human glioblastoma cell lines.

J. Redpath, R. Antoniono, H. Ross, 1997, European journal of cancer.

Prophylactic cranial irradiation in small-cell lung cancer: findings from a North Central Cancer Treatment Group Pooled Analysis.

N. Foster, A. Adjei, K. Olivier, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Outcomes of minimally invasive esophagectomy in esophageal cancer after neoadjuvant chemoradiotherapy.

J. Ashman, K. Harold, S. Warner, 2014, The Annals of thoracic surgery.

PRONOUNCE: Randomized, Open-Label, Phase III Study of First-Line Pemetrexed + Carboplatin Followed by Maintenance Pemetrexed versus Paclitaxel + Carboplatin + Bevacizumab Followed by Maintenance Bevacizumab in Patients ith Advanced Nonsquamous Non–Small-Cell Lung Cancer

C. Obasaju, R. Govindan, D. Spigel, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A Randomized Phase II Study of Gemcitabine and Carboplatin with or without Cediranib as First-Line Therapy in Advanced Non–Small-Cell Lung Cancer: North Central Cancer Treatment Group Study N0528

S. Mandrekar, A. Adjei, A. Adjei, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Single-Agent Versus Combination Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer and a Performance Status of 2: Prognostic Factors and Treatment Selection Based on Two Large Randomized Clinical Trials

M. Socinski, K. O'Byrne, J. Singer, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A Case of Donor-Transmitted Non-Small Cell Lung Cancer After Liver Transplantation: An Unwelcome Guest.

K. Halling, D. Douglas, M. Sonbol, 2019, The oncologist.

Original Paper High and Low Dose Rate Irradiation Have Opposing Effects on Cytokine Gene Expression in Human Glioblastoma Cell Lines

J. Redpath, R. Antoniono, H. Ross, 1997 .

Cyclosporin A enhances paclitaxel toxicity against leukemia and respiratory epithelial cancers.

L. Slater, H. Ross, A. Cañada, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

A new scoring system for predicting survival in patients with non-small cell lung cancer

J. Sloan, Ping Yang, J. Wampfler, 2015, Cancer medicine.

Randomized Phase II Study of Gemcitabine Plus Cisplatin or Carboplatin, With or Without Cetuximab, As First-Line Therapy for Patients With Advanced or Metastatic Non–Small-Cell Lung Cancer

F. Shepherd, P. Ellis, D. Ellison, 2007 .

Expert Consensus Document on Pulmonary Metastasectomy.

H. Pass, P. Fidias, M. Lanuti, 2019, The Annals of thoracic surgery.

Long‐Term Results of a Trial of Concurrent Chemotherapy and Escalating Doses of Radiation for Unresectable Non–Small Cell Lung Cancer: NCCTG N0028 (Alliance)

J. Jett, S. Hillman, A. Tan, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Incidence of brain metastasis from esophageal cancer.

D. Fleischer, J. Ashman, F. Ramirez, 2017, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer

L. Freitag, J. von Pawel, U. Gatzemeier, 2008, British Journal of Cancer.

Paraneoplastic polymyositis associated with mesothelioma: A brief report

G. Petris, J. Camoriano, B. Burnette, 2010 .

A randomized, multicenter study to determine the safety and efficacy of the immunoconjugate SGN-15 plus docetaxel for the treatment of non-small cell lung carcinoma.

C. Rudin, R. Figlin, L. Hart, 2006, Lung cancer.

Outcomes of patients with loco-regionally recurrent or new primary squamous cell carcinomas of the head and neck treated with curative intent reirradiation at Mayo Clinic

H. Kosiorek, M. Halyard, R. Foote, 2016, Radiation Oncology.

Prophylactic cranial irradiation in small-cell lung cancer: Findings from a North Central Cancer Treatment Group Pooled Analysis.

N. Foster, A. Adjei, K. Olivier, 2012 .

Phase II trial of atezolizumab before and after definitive chemoradiation for unresectable stage III NSCLC.

E. Vokes, D. Kozono, T. Stinchcombe, 2018 .

AFT-16: Phase II trial of neoadjuvant and adjuvant atezolizumab and chemoradiation (CRT) for stage III non-small cell lung cancer (NSCLC).

E. Vokes, D. Kozono, T. Stinchcombe, 2021 .

Small-cell Lung Cancer in Very Elderly (≥ 80 Years) Patients.

Steven E Schild, Ping Yang, Jason A Wampfler, 2019, Clinical lung cancer.

A Randomized Phase II Study of Linsitinib (OSI-906) Versus Topotecan in Patients With Relapsed Small-Cell Lung Cancer

J. Nieva, M. Schell, T. Owonikoko, 2016, The oncologist.

Randomized phase II study of carboplatin and etoposide with or without obatoclax mesylate in extensive-stage small cell lung cancer.

M. Berger, P. Zatloukal, C. Langer, 2014, Lung cancer.

Acute Toxicities and Short-Term Patient Outcomes After Intensity-Modulated Proton Beam Radiation Therapy or Intensity-Modulated Photon Radiation Therapy for Esophageal Carcinoma: A Mayo Clinic Experience

C. Hallemeier, T. Sio, J. Ashman, 2020, Advances in radiation oncology.

Analysis of prognostic factors in patients with advanced relapsed/refractory NSCLC: Cox regression analysis of a randomized phase III trial comparing docetaxel and paclitaxel poliglumex (PPX).

M. Socinski, K. O'Byrne, L. Paz-Ares, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Malignant peritoneal mesothelioma with possible hormone association and multiple endocrine neoplasia in a young female with an indolent clinical course

H. Tazelaar, J. Kriegshauser, J. Kling, 2014 .

Outcomes of patients with loco-regionally recurrent or new primary squamous cell carcinomas of the head and neck treated with curative intent reirradiation at Mayo Clinic

H. Kosiorek, M. Halyard, R. Foote, 2016, Radiation oncology.

Incidence and impact of postoperative atrial fibrillation after minimally invasive esophagectomy.

J. Ashman, K. Harold, D. Jaroszewski, 2016, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

NCCTG N0821 (Alliance): A Phase II First-Line Study of Pemetrexed, Carboplatin, and Bevacizumab in Elderly Patients with Advanced Nonsquamous Non–Small-Cell Lung Cancer With Good Performance Status

S. Mandrekar, M. Aubry, A. Adjei, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A randomized phase II study of gemcitabine (G) and carboplatin (C) with or without cediranib (AZD2171 [CED]) as first-line therapy in advanced non-small cell lung cancer (NSCLC).

S. Mandrekar, A. Adjei, G. Dy, 2010 .

Optimizing obatoclax administration schedule: Safety and efficacy of 3-hour versus 24-hour infusion in combination with carboplatin and etoposide for patients with extensive-stage small cell lung cancer (ES-SCLC).

R. Salgia, J. Stephenson, A. Chiappori, 2010 .

The antiproliferative effect of trans-retinoic acid is associated with selective induction of interleukin-1 beta, a cytokine that directly inhibits growth of lung cancer cells.

H. Ross, 1996, Oncology research.

Randomized Phase II Multicenter Trial of Two Schedules of Lapatinib as First- or Second-Line Monotherapy in Patients with Advanced or Metastatic Non–Small Cell Lung Cancer

J. Rigas, F. Shepherd, M. Smylie, 2010, Clinical Cancer Research.

A phase I study of MEDI1873, a novel GITR agonist, in advanced solid tumors.

N. Rizvi, P. Vicini, J. Infante, 2018, Annals of Oncology.

Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer

L. Freitag, U. Gatzemeier, L. Paz-Ares, 2008, British Journal of Cancer.

PD-081 A phase 2 randomized study of GM-CSF gene-modifiedautologous tumor vaccine (CG8123) with and without low-dose cyclophosphamide in advanced stage non-small cell lung cancer (NSCLC)

D. Carbone, J. Nemunaitis, K. Kelly, 2005 .